Starting July 1, Medicare will launch a new pilot program that lets many Part D beneficiaries buy certain GLP‑1 weight‑loss medications for $50 per month. The Medicare GLP‑1 Bridge, announced by HHS and CMS, runs from July 1 through December 31, 2027, and is expected to make these drugs more affordable for an estimated 14 million people.
Who may qualify
– Participants must be enrolled in Medicare Part D and be prescribed a GLP‑1 medication for weight loss or weight management. The program is open to adults aged 18 and older who meet clinical prescribing requirements under the demonstration. Beneficiaries should check with their Part D plan for exact eligibility and enrollment details.
Drugs included and limits
– The pilot covers certain formulations of Wegovy, Foundayo, and Zepbound KwikPens at a $50 monthly copay for eligible participants. Some Zepbound single‑use pens and vial formulations are excluded. The program applies only to covered formulations and a limited supply as defined by the demonstration.
Costs and Medicare rules
– The $50 monthly copay is a flat price for covered GLP‑1 products in the pilot, but these payments do not count toward the annual Part D deductible or the out‑of‑pocket spending cap. For context, the Part D deductible can be up to $615 in 2026, and the catastrophic out‑of‑pocket threshold is $2,100 in 2026. Self‑pay prices for GLP‑1s outside programs can range widely, from roughly $149 per month to over $1,300 per month depending on product and purchase route.
Why officials launched the pilot
– CMS says the goal is to increase access to treatments that can produce clinically significant weight loss and improve related health conditions, especially for people who could not afford them previously. The bridge follows earlier federal efforts to lower drug costs and is described as a temporary, subsidized demonstration to assess the real‑world effects of broader access.
What experts say
– Clinicians and policy experts welcome the improved access and lower out‑of‑pocket costs for many beneficiaries, noting these medicines can be a major advance for obesity treatment. They say the program could help patients start effective therapy who otherwise couldn’t afford it.
Concerns and limitations
– The demonstration lasts about 18 months, so patients who begin therapy under the bridge may face higher costs or loss of access when the pilot ends, risking treatment interruption and potential weight regain. The $50 copays not counting toward deductibles and spending caps is another drawback highlighted by analysts. Experts also point out the program is temporary and depends on insurer participation and future policy decisions; it will serve as a test case to see how broader access affects overall health spending.
About GLP‑1 medications
– GLP‑1 drugs suppress appetite and help control blood sugar. They are approved for weight management and for treating type 2 diabetes in various formulations, including weekly injections and daily oral tablets. Common examples beyond the three drugs in this demonstration include Ozempic, Rybelsus, and Mounjaro. Typical side effects can include nausea, dizziness, headache, fatigue, diarrhea or constipation, and bloating.
Practical takeaways
– If you have Medicare Part D and are interested, contact your plan or prescriber to learn whether you qualify, which formulations are covered, and how to enroll once the program begins July 1. Keep in mind the demonstration’s time limit and plan for long‑term management with your clinician, including lifestyle measures such as diet, exercise, strength training, and sleep to help sustain weight loss alongside medication.
Disclaimer
– This summary is informational. Ask your doctor or Medicare plan for guidance tailored to your health needs and coverage situation.
